Ofatumumab

Trade Name: 
Kesimpta
Manufacturer/Distributor: 
Novartis Pharmaceuticals
Classification: 
Immunomudulator
ATC Class: 
L01XC10 - ofatumumab
Status: 
active
Notice of Compliance (yyyy/mm/dd): 
2021/01/22
Date Marketed in Canada (yyyy/mm/dd): 
2021/04/08
Presentation: 
20 mg/0.4 mL injection. DIN: 02511355 (pre-filled pen)
20 mg/0.4 mL injection. DIN: 02511363 (pre-filled syringe)
Comments: 
For treatment of adults with relapsing remitting multiple sclerosis.